Generic Name: cysteamine
Brand Name: Cystadrops
Manufacturer: Recordati Rare Diseases Canada Inc.
Indications: Corneal cystine crystal deposits
Manufacturer Requested Reimbursement Criteria1: For the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input posted||November 02, 2018|
|Patient group input closed||December 20, 2018|
- No patient input submission received
|Submission received||December 10, 2018|
|Submission accepted for review||December 24, 2018|
|Review initiated||January 02, 2019|
|Draft CADTH review report(s) sent to applicant||March 25, 2019|
|Comments from applicant on draft CADTH review report(s) received||April 03, 2019|
|Redaction requests from applicant on draft CADTH review report(s) received||April 10, 2019|
|CADTH review team's comments on draft CADTH review report(s) sent to applicant||May 03, 2019|
|Canadian Drug Expert Committee (CDEC) meeting||May 15, 2019|
|CDEC recommendation & redacted CADTH review report(s) sent to applicant and drug plans||May 28, 2019|
May 30, 2019